WO2002059270A8 - Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo - Google Patents

Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo

Info

Publication number
WO2002059270A8
WO2002059270A8 PCT/US2002/002016 US0202016W WO02059270A8 WO 2002059270 A8 WO2002059270 A8 WO 2002059270A8 US 0202016 W US0202016 W US 0202016W WO 02059270 A8 WO02059270 A8 WO 02059270A8
Authority
WO
WIPO (PCT)
Prior art keywords
smooth muscle
muscle cells
methods
vivo
compositions
Prior art date
Application number
PCT/US2002/002016
Other languages
English (en)
Other versions
WO2002059270A2 (fr
WO2002059270A3 (fr
Inventor
Gary K Owens
Ichiro Manabe
Original Assignee
Setagon Inc
Gary K Owens
Ichiro Manabe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Setagon Inc, Gary K Owens, Ichiro Manabe filed Critical Setagon Inc
Priority to AU2002237928A priority Critical patent/AU2002237928A1/en
Priority to CA002435631A priority patent/CA2435631A1/fr
Priority to EP02704234A priority patent/EP1360191A4/fr
Publication of WO2002059270A2 publication Critical patent/WO2002059270A2/fr
Publication of WO2002059270A3 publication Critical patent/WO2002059270A3/fr
Publication of WO2002059270A8 publication Critical patent/WO2002059270A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne en règle générale des promoteurs, des amplificateurs et autres éléments régulateurs de cellules de muscle lisse. L'invention concerne plus particulièrement des procédés pour l'inactivation ou la surexpression ciblée de gènes visés, dans les cellules de muscle lisse ou dans un sous-type de ces cellules. L'invention concerne également des procédés pour l'expression de polynucléotides in vivo spécifiquement dans les cellules de muscle lisse ou dans des sous-types de ces cellules.
PCT/US2002/002016 2001-01-24 2002-01-24 Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo WO2002059270A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002237928A AU2002237928A1 (en) 2001-01-24 2002-01-24 Methods and compositions for expressing polynucleotides specifically in smooth muscle cells in vivo
CA002435631A CA2435631A1 (fr) 2001-01-24 2002-01-24 Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo
EP02704234A EP1360191A4 (fr) 2001-01-24 2002-01-24 Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26381101P 2001-01-24 2001-01-24
US60/263,811 2001-01-24

Publications (3)

Publication Number Publication Date
WO2002059270A2 WO2002059270A2 (fr) 2002-08-01
WO2002059270A3 WO2002059270A3 (fr) 2003-03-27
WO2002059270A8 true WO2002059270A8 (fr) 2003-11-06

Family

ID=23003314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002016 WO2002059270A2 (fr) 2001-01-24 2002-01-24 Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo

Country Status (4)

Country Link
EP (1) EP1360191A4 (fr)
AU (1) AU2002237928A1 (fr)
CA (1) CA2435631A1 (fr)
WO (1) WO2002059270A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234972A1 (en) * 2001-03-20 2004-11-25 Owens Gary K. Method for identifying and purifying smooth muscle progenitor cells
CN102676527B (zh) * 2012-05-29 2013-09-25 山东农业大学 一种骨骼肌特异性MYHC-IIx启动子及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305091D0 (en) * 1993-03-12 1993-04-28 Thrombosis Res Inst Eukaryotic expression vectors driven by a novel strong mammalian cell promoter
DE19620308A1 (de) * 1996-05-10 1997-11-13 Franz Wolfgang M Dr Vektor-System zur spezifischen in vivo Genexpression in glatten Gefäßmuskelzellen
WO1999036101A1 (fr) * 1998-01-16 1999-07-22 The University Of Virginia Patent Foundation Identification d'un promoteur/activateur de chaines lourdes de myosine des muscles lisses (sm-mhc), specifique aux cellules musculaires lisses

Also Published As

Publication number Publication date
AU2002237928A1 (en) 2002-08-06
EP1360191A2 (fr) 2003-11-12
EP1360191A4 (fr) 2004-08-25
CA2435631A1 (fr) 2002-08-01
WO2002059270A2 (fr) 2002-08-01
WO2002059270A3 (fr) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2003062394A3 (fr) Methodes et compositions d'interference arn
WO2001023386A3 (fr) Derives de benzodiazepine, preparation et utilisation desdits derives
IL166710A0 (en) Process for the preparation of 4-ÄÄ4-ÄÄ-(2-cyanoethenyl)2,6-dimethylphenylÜaminoÜ-2-pyrimidinylÜaminoÜbenzonitrile
EP1709195A4 (fr) Formulations de transfection cellulaire de petits arn interferents, compositions correspondantes et procedes de production et d'utilisation
WO2001068836A3 (fr) Procedes et compositions d'interference d'arn
WO2006078414A3 (fr) Methodes et compositions dans lesquelles sont utilises des siarn comme mediateurs de l'interference arn
HK1052000A1 (en) Process of preparing tolterodine and analogues there of as well as intermediates prepared in the process.
WO2004015085A3 (fr) Procede et compositions relatives a des acides ribonucleiques 5'-chimeriques
WO2004006834A3 (fr) Analogues de leflunomide pour traiter l'arthrite rhumatoide
WO2005016883A3 (fr) Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
AU2002243972A1 (en) Compositions and methods relating to breast specific genes and proteins
EP1163252A4 (fr) Compositions, kits et procedes concernant le gene fez1 de l'homme, nouveau gene suppresseur des tumeurs
WO2004029283A3 (fr) Sondes d'adn subtelomeriques et leur procede de production
WO2005001042A8 (fr) Cellules precurseurs de muscle lisse
WO2002059270A8 (fr) Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo
WO2002024867A3 (fr) Nouvelles compositions et nouvelles methodes pour le diagnostic et le traitement des lymphomes et des leucemies
GB0304379D0 (en) Roller-typed paintbrush's structural improvement
WO2005012275A3 (fr) Composes benzo[1,2,5]thiadiazole
AU2003302820A1 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
GB2418915A (en) Fragrance compositions comprising benzo[4,5]thieno[3,2-B]pyran-2-one
WO1999002724A3 (fr) Procede d'identification de genes exprimes dans des lignees selectionnees et nouveaux genes identifies au moyen de ces procedes
AU2003222667A1 (en) 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2004050834A3 (fr) Gpc99 et gpc99a: compositions et methodes de traitement du cancer
WO2005021776A3 (fr) Methodes d'utilisation d'une rnase h de mammifere et de compositions a base de celle-ci
AU2003297696A1 (en) Compositions,splice variants and methods relating to breast specific genes and proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2435631

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002704234

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 31/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

WWP Wipo information: published in national office

Ref document number: 2002704234

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002704234

Country of ref document: EP